Genetic testing supports prostate cancer treatment
Testing for three genes linked to aging, FGFR1, PMP22 and CDKN1A, can help predict how aggressive prostate cancer will be, which could be important in helping many men avoid aggressive treatments when their cancer is expected to be slow-growing.
This is the result of a study published in the journal Science Translational Medicine on September 11 in the US.
Photo for illustration purposes only. (Source: AFP).
According to the team of scientists, these three genes are particularly affected by cellular senescence, a process known to play a major role in preventing tumor growth and is associated with benign prostate lesions in mice and humans. When these genes are present, prostate cancer tumors are low risk.
Prostate cancers that test negative for these genes are more likely to become aggressive cancers.
US scientists tested the accuracy of their diagnoses based on biopsy samples of 43 patients followed for at least 10 years.
All of these patients were initially diagnosed with low-risk prostate cancer. They found that 14 of them had advanced tumors, and all of these patients were identified by testing for the above genes./.
According to (TTXVN) - VT
;
Other news
- Russia installs world's largest optical telescope(04/09/2013)
- Magmatic water discovered on the surface of the Moon(04/09/2013)
- Japan proceeds to "bury" CO2 gas under the seabed(05/09/2013)
- Developing new technology for early detection of brain tumors(05/09/2013)
- New hope for heart attack patients(06/09/2013)
- Bacteria in the human gut may help fight obesity(08/09/2013)
- Iran announces preparations to send living creatures into space(08/09/2013)
- Vinh University opens Seafood Practice Center(10/09/2013)
- Hybrid technology - technology of the future(12/09/2013)
- The MERS virus was transmitted from animals to humans.(20/09/2013)
.
.
.
.
.
;){kind=link}